FDA approved teatment for rare disease affecting optic nerves, spinal cord
On Aug. 17, 2020, the FDA approved Genentech’s Enspryng (satralizumab-mwge) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults with a particular antibody οΎ patients who are anti-aquaporin-4 or AQP4 antibody-positive. NMOSD is a rare autoimmune disease of the central nervous system that mainly affects the optic nerves and spinal cord. Enspryng is the third approved treatment for the disorder.
Tags:
Source: U.S. Food and Drug Administration
Credit:
